Business

Around the Region

Death ‘likely unrelated’ to MS pill

The biotechnology company Biogen Idec Inc. said Monday that it was investigating the death of a patient who took its new multiple sclerosis pill, Tecfidera.

But the Weston company said the death was “likely unrelated” to the medication, based on preliminary findings.

Advertisement

Spokeswoman Kate Niazi-Sai said company safety officials learned late last week that a 59-year-old woman who had taken Tecfidera for 5½ weeks died 2½ weeks after she stopped taking the pill.

Niazi-Sai said the patient discontinued taking Tecfidera because of gastrointestinal side effects such as nausea, vomiting, and diarrhea.

Get Business Headlines in your inbox:
The Globe's latest business headlines delivered every morning, Monday through Friday.
Thank you for signing up! Sign up for more newsletters here

But the cause of death was bilateral pneumonia, a condition that occurs more frequently in multiple sclerosis patients than in the general public, Niazi-Sai said.

Apparently, gastrointestinal issues did not cause the death, the Biogen Idec spokeswoman said.

In a note to investors, a biotechnology analyst, Mark Schoenebaum of ISI Group in New York, described the event as a “non-issue” for Biogen Idec.

Robert Weisman

Robert Weisman can be reached at weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.